Skip to main content

Table 2 Influence of pioglitazone on glycaemic and lipid profile, weight and BMI in patients with T2DM

From: Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis

Author, year FPG* (mmol/l) HbA1c* (%) Total cholesterol* (mmol/l) LDL* (mmol/l) HDL* (mmol/l) Triglycerides* (mmol/l) BMI* (kg/m2) Weight* (kg)
Berhanu et al. [13] 0.47 (− 0.14; 1.09) − 1.60 (− 1.82; − 1.38) 0.15 (0.01; 0.27) 0.10 (− 0.02; 0.22) 0.11 (0.07; 0.15) − 0.002 (− 0.22; 0.22)   
Belfort et al. [14] − 1.11 (− 1.93; − 0.29) − 0.70 (− 1.35; − 0.05) 0.13 (− 0.36; 0.61) 0.05 (− 0.41; 0.52) 0.08 (− 0.05; 0.20) − 0.27 (− 0.80; 0.25) 1.1 (− 1.79; 3.99) 2.5 (− 7.97; 12.97)
DeFronzo et al. [16] − 0.59 (− 0.67; − 0.50)     0.50 (0.49; 0.51) − 1.1 (− 1.17; − 1.03) 1.4 (1.32; 1.48) 3.8 (3.60; 4.00)
DeFronzo et al. [17] − 0.22 (− 0.23; − 0.21)       1.6 (1.21; 1.99)  
Mattoo et al. [15] − 1.22 (− 2.24; − 0.20) − 0.74 (− 1.01; − 0.47)   − 0.2 (− 0.24; 0.20) 0.12 (0.04; 0.19)    
Rosenstock et al. (15 mg) [18] − 1.91 (− 2.46; − 1.37) − 0.99 (− 1.15; − 0.83)   0.13 (0.04; 0.22) 0.18 (0.10; 0.26) 0.06 (− 0.09; 0.21)   
Rosenstock et al. (30 mg) [18] − 2.67 (− 3.22; − 2.12) − 1.26 (− 1.42; − 1.10)   0.07 (− 0.02; 0.02) 0.24 (0.16; 0.32) − 0.12 (− 0.26; 0.03)   
Davidson et al. (30 mg) [19] − 1.77 (− 2.21; − 1.33) − 1.20 (− 1.36; − 1.04)   0.17 (0.08; 0.25) 0.25 (0.19; 0.31) − 0.05 (− 0.12; 0.01)   
Davidson et al. (45 mg) [19] − 2.54 (− 2.98; − 2.11) − 1.50 (− 1.66; − 1.34)   0.17 (0.08; 0.26) 0.34 (0.27; 0.40) − 0.07 (− 0.13; − 0.002)   
Goldberg et al. [3] − 1.84 (− 2.08; − 1.60) − 0.70 (− 0.90; − 0.50) 0.23 (0.13; 0.32) 0.32 (0.24; 0.40) 0.13 (0.11; 0.16) − 0.59 (− 0.76; − 0.41)   2.0 (1.64; 2.39)
Panikar et al. (7.5 mg) [22]   − 1.24 (− 2.51; 0.03)      0.88 (− 4.55; 6.31) 0.33 (− 1.65; 2.31)
Panikar et al. (15 mg) [22]   − 1.18 (− 2.34; − 0.02)      1.62 (− 4.08; 7.32) 0.62 (− 1.54; 2.78)
Panikar et al. (30 mg) [22]   − 1.25 (− 2.90; 0.40)      2.72 (− 3.10; 8.54) 1.03 (− 1.20; 3.26)
Xu et al. [20] − 2.00 (− 2.39; − 1.61) − 1.50 (− 1.70; − 1.30) − 0.10 (− 0.30; 0.10) − 0.10 (− 0.30; 0.10) 0.16 (0.12; 0.20) − 0.20 (− 0.40; − 0.004) 0.00 (− 0.20; 0.20) 0.00 (− 0.78; 0.78)
Yoshii et al. [25]     − 0.22 (− 0.33; − 0.08) 0.12 (0.05; 0.19)    
Bolli et al. [12] − 1.60 (− 1.95; − 1.33) − 0.60 (− 0.71; − 0.45)       2.60 (2.01; 3.19)
Kodama et al. [23]   − 0.36 (− 0.73; 0.01)   − 0.01 (− 0.34; 0.32) 0.14 (− 0.03; 0.31)    0.60 (− 5.45; 6.65)
Shah et al. [24]   − 0.5 (− 0.77; − 0.23)      1.5 (1.11; 1.89) 4.9 (− 3.92; 13.72)
Gerber et al. (30 mg) [21] − 2.6 (− 1.39; − 0.90) − 1.1 (− 3.26; 1.06) − 0.13 (− 1.87; 1.61) − 0.01 (− 1.56; 1.54) 0.11 (− 0.68; 0.68) − 0.87 (− 3.03; 4.77)   2.6 (− 2.89; 8.09)
Gerber et al. (30/45 mg) [21] − 1.9 (− 1.38; − 0.73) − 1.1 (− 3.84; 1.64) − 0.03 (− 2.62; 2.56) − 0.12 (− 1.69; 1.45) 0.12 (− 0.55; 0.79) − 0.60 (− 4.56; 5.16)   2.7 (− 3.18; 8.58)
Gerber et al. (45 mg) [21] − 1.5 (− 1.23; − 0.52) − 0.9 (− 4.04; 2.24)   − 0.12 (− 1.61; 1.37) 0.08 (− 0.37; 0.53) − 0.28 (− 3.28; 2.72)   2.8 (− 3.67; 9.27)
  1. * Weighted mean difference (95% CI)